TY  - JOUR 
AU  - Gaibar Alonso, María
AU  - Novillo, Apolonia
AU  - Romero-Lorca, Alicia
AU  - Malón, Diego
AU  - Antón, Beatriz
AU  - Moreno, Amalia
AU  - Fernández-Santander, Ana
PY  - 2022
UR  - http://hdl.handle.net/20.500.12020/1825
AB  - HER2-positive breast cancer (BC) is an aggressive subtype that affects 20–25% of BC patients. For these patients, neoadjuvant therapy is a good option that targets a pathological complete response (pCR) and more breast-conserving surgery. In effect,...
LA  - en
PB  - MDPI
TI  - FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
DO  - https://doi.org/10.3390/pharmaceutics14020242
T2  - Pharmaceutics
M2  - 1
KW  - HER2-positive breast cancer
KW  - FGFR1 gene
KW  - CNVs
KW  - Miller–Payne grading
KW  - Anti-HER2 treatment
KW  - Pathological complete response
VL  - 14
ER  -